Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05028582 · ClinicalTrials.gov registry record · Phase 3
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
A Phase 3 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 432
- Enrollment target
NCT05028582 is a Phase 3 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 432 participants.
The verdict
NCT05028582, a Phase 3 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 432 participants
- Enrollment target
Study Summary
This was a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-154) 0.3% foam vs vehicle foam applied once daily (qd) for 8 weeks by participants with plaque psoriasis of the scalp and body.
Interventions
- DRUG Vehicle Foam
- DRUG Roflumilast Foam 0.3%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2021-08-24 |
| Est. Completion | 2022-06-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05028582
The ClinicalTrials.gov registry entry for NCT05028582 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Foam is the first listed.
NCT05028582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05028582 about?
NCT05028582 is a clinical study titled "Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)". This was a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-154) 0.3% foam vs vehicle foam applied once daily (qd) for 8 weeks by participants with plaque psoriasis of the scalp and body.
What is the current status of trial NCT05028582?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 432 participants. The study started on 2021-08-24. Estimated completion is 2022-06-03.
What interventions are being tested in trial NCT05028582?
The interventions under investigation include: Vehicle Foam (DRUG), Roflumilast Foam 0.3% (DRUG).
Who is sponsoring clinical trial NCT05028582?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.